Experimental drug NU-9 – a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) – improves neuron health in animal models of Alzheimer’s disease, according to a new Northwestern University study.